These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23391372)

  • 1. Serum M65 as a biomarker for metastatic renal cell carcinoma.
    Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
    Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
    Bilici A; Ustaalioglu BB; Ercan S; Orcun A; Seker M; Salepci T; Gumus M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):309-16. PubMed ID: 20967544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
    Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
    Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of serum M30 and M65 levels in patients with breast cancer.
    Tas F; Karabulut S; Yildiz I; Duranyildiz D
    Biomed Pharmacother; 2014 Oct; 68(8):1135-40. PubMed ID: 25465151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
    J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
    Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
    Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma.
    Sen F; Yildiz I; Odabas H; Tambas M; Kilic L; Karadeniz A; Altun M; Ekenel M; Serilmez M; Duranyildiz D; Bavbek S; Basaran M
    Tumour Biol; 2015 Feb; 36(2):1039-44. PubMed ID: 25326440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of serum M30 and M65 levels in melanoma.
    Tas F; Karabulut S; Serilmez M; Yildiz I; Sen F; Ciftci R; Duranyildiz D
    Melanoma Res; 2013 Oct; 23(5):390-5. PubMed ID: 23812330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.
    Yildiz I; Tas F; Kilic L; Sen F; Saip P; Eralp Y; Keskin S; Karabulut S; Ciftci R; Serilmez M; Yasasever V; Aydiner A
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):437-44. PubMed ID: 23801282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
    Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
    Chu T; Jiang L; Ying W; Han B
    Clin Transl Oncol; 2017 Mar; 19(3):326-331. PubMed ID: 27468866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls.
    Oven Ustaalioglu B; Bilici A; Ercan S; Orcun A; Seker M; Ozkan A; Ustaalioglu R; Gumus M
    Clin Transl Oncol; 2012 May; 14(5):356-61. PubMed ID: 22551541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.
    Tas F; Karabulut S; Bilgin E; Sen F; Yildiz I; Tastekin D; Ciftci R; Duranyildiz D
    Tumour Biol; 2013 Dec; 34(6):3529-36. PubMed ID: 23784459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.
    Ustaalioglu BB; Bilici A; Ercan S; Seker M; Orcun A; Gumus M
    Med Oncol; 2013 Jun; 30(2):551. PubMed ID: 23536001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
    Nagel M; Schulz J; Maderer A; Goepfert K; Gehrke N; Thomaidis T; Thuss-Patience PC; Al-Batran SE; Hegewisch-Becker S; Grimminger P; Galle PR; Möhler M; Schattenberg JM
    Tumour Biol; 2018 Mar; 40(3):1010428318764007. PubMed ID: 29534639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure.
    Zheng SJ; Liu S; Liu M; McCrae MA; Li JF; Han YP; Xu CH; Ren F; Chen Y; Duan ZP
    World J Gastroenterol; 2014 Mar; 20(9):2403-11. PubMed ID: 24605039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival.
    Ulukaya E; Yilmaztepe A; Akgoz S; Linder S; Karadag M
    Lung Cancer; 2007 Jun; 56(3):399-404. PubMed ID: 17316892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum profiles of M30, M65 and interleukin-17 compared with C-reactive protein in patients with mild and severe acute pancreatitis.
    Vlachos S; Tsaroucha AK; Konstantoudakis G; Papachristou F; Trypsianis G; Schizas D; Vaos G; Simopoulos C
    J Hepatobiliary Pancreat Sci; 2014 Dec; 21(12):911-8. PubMed ID: 25214429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum levels of cell death circulating biomarkers, M30 and M65, in patients with β-thalassemia major.
    Esmaeil N; Moayedi B; Gharagozloo M; Maracy MR
    Hemoglobin; 2013; 37(4):404-10. PubMed ID: 23600495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
    Vermaat JS; Gerritse FL; van der Veldt AA; Roessingh WM; Niers TM; Oosting SF; Sleijfer S; Roodhart JM; Beijnen JH; Schellens JH; Gietema JA; Boven E; Richel DJ; Haanen JB; Voest EE
    Eur Urol; 2012 Oct; 62(4):685-95. PubMed ID: 22285764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.